NASDAQ · ENTO
Entero Therapeutics, Inc.
$2.99 +$0.15 (+5.28%) 1DKey Metrics
$7.79M
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$7.79M
Enterprise value—
Shares outstanding2.1M
52-wk range$1.08 – $5.84
Avg volume · 20D493.4K
Net cash
—
Book value / share—
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Entero Therapeutics, Inc.
IPO dateOct 11, 2016
Employees2
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
—
Needs two fiscal years of filings
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value